Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Development of Pharmacotherapies for the Treatment of Sarcopenia.

Rooks D, Roubenoff R.

J Frailty Aging. 2019;8(3):120-130. doi: 10.14283/jfa.2019.11.

PMID:
31237312
2.

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.

Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U.

J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20.

PMID:
30894455
3.

Emerging Interventions for Elderly Patients-The Promise of Regenerative Medicine.

Miller RR, Roubenoff R.

Clin Pharmacol Ther. 2019 Jan;105(1):53-60. doi: 10.1002/cpt.1272. Epub 2018 Dec 5.

PMID:
30387136
4.

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.

Grunseich C, Miller R, Swan T, Glass DJ, El Mouelhi M, Fornaro M, Petricoul O, Vostiar I, Roubenoff R, Meriggioli MN, Kokkinis A, Guber RD, Budron MS, Vissing J, Soraru G, Mozaffar T, Ludolph A, Kissel JT, Fischbeck KH; BVS857 study group.

Lancet Neurol. 2018 Dec;17(12):1043-1052. doi: 10.1016/S1474-4422(18)30320-X. Epub 2018 Oct 15.

PMID:
30337273
5.

The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants.

Marzetti E, Cesari M, Calvani R, Msihid J, Tosato M, Rodriguez-Mañas L, Lattanzio F, Cherubini A, Bejuit R, Di Bari M, Maggio M, Vellas B, Dantoine T, Cruz-Jentoft AJ, Sieber CC, Freiberger E, Skalska A, Grodzicki T, Sinclair AJ, Topinkova E, Rýznarová I, Strandberg T, Schols AMWJ, Schols JMGA, Roller-Wirnsberger R, Jónsson PV, Ramel A, Del Signore S, Pahor M, Roubenoff R, Bernabei R, Landi F; SPRINTT Consortium.

Exp Gerontol. 2018 Nov;113:48-57. doi: 10.1016/j.exger.2018.09.017. Epub 2018 Sep 24.

6.

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS.

Am J Respir Crit Care Med. 2019 Feb 1;199(3):313-320. doi: 10.1164/rccm.201802-0286OC.

7.

How soon will digital endpoints become a cornerstone for future drug development?

Boehme P, Hansen A, Roubenoff R, Scheeren J, Herrmann M, Mondritzki T, Ehlers J, Truebel H.

Drug Discov Today. 2019 Jan;24(1):16-19. doi: 10.1016/j.drudis.2018.07.001. Epub 2018 Jul 17.

PMID:
30009955
8.

Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, Laurent D, Rooks D, Rondon JC, Roubenoff R.

Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919. doi: 10.1111/cen.13601. Epub 2018 Apr 22.

PMID:
29566437
9.

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

Vellas B, Fielding RA, Bens C, Bernabei R, Cawthon PM, Cederholm T, Cruz-Jentoft AJ, Del Signore S, Donahue S, Morley J, Pahor M, Reginster JY, Rodriguez Mañas L, Rolland Y, Roubenoff R, Sinclair A, Cesari M.

J Frailty Aging. 2018;7(1):2-9. doi: 10.14283/jfa.2017.30.

PMID:
29412436
10.

Alterations in the in vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of sarcopenia.

Brzeszczyńska J, Meyer A, McGregor R, Schilb A, Degen S, Tadini V, Johns N, Langen R, Schols A, Glass DJ, Roubenoff R, Ross JA, Fearon KCH, Greig CA, Jacobi C.

J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):93-105. doi: 10.1002/jcsm.12252. Epub 2017 Dec 6.

11.

Reply to: New Hope for Sarcopenia.

Rooks D, Roubenoff R.

J Am Geriatr Soc. 2018 Jan;66(1):208-209. doi: 10.1111/jgs.15187. Epub 2017 Nov 17. No abstract available.

PMID:
29148045
12.

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.

Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R.

J Am Geriatr Soc. 2017 Sep;65(9):1988-1995. doi: 10.1111/jgs.14927. Epub 2017 Jun 27.

PMID:
28653345
13.

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M.

Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042. Epub 2017 Aug 2.

PMID:
28643356
14.

Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study.

Saber H, Himali JJ, Beiser AS, Shoamanesh A, Pikula A, Roubenoff R, Romero JR, Kase CS, Vasan RS, Seshadri S.

Stroke. 2017 Jul;48(7):1760-1765. doi: 10.1161/STROKEAHA.116.016563. Epub 2017 Jun 8.

15.

Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, Huang Y, Chivers S, Valentin MA, Borah B, Roubenoff R, Junker U, Jakob F.

J Clin Invest. 2017 Jun 1;127(6):2148-2158. doi: 10.1172/JCI83731. Epub 2017 Apr 24.

16.

Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial.

Cesari M, Landi F, Calvani R, Cherubini A, Di Bari M, Kortebein P, Del Signore S, Le Lain R, Vellas B, Pahor M, Roubenoff R, Bernabei R, Marzetti E; SPRINTT Consortium.

Aging Clin Exp Res. 2017 Feb;29(1):81-88. doi: 10.1007/s40520-016-0716-1. Epub 2017 Feb 10.

PMID:
28188558
17.

Physical frailty and sarcopenia (PF&S): a point of view from the industry.

Del Signore S, Roubenoff R.

Aging Clin Exp Res. 2017 Feb;29(1):69-74. doi: 10.1007/s40520-016-0710-7. Epub 2017 Feb 3. Review.

PMID:
28160253
18.

The need of operational paradigms for frailty in older persons: the SPRINTT project.

Cesari M, Marzetti E, Calvani R, Vellas B, Bernabei R, Bordes P, Roubenoff R, Landi F, Cherubini A; SPRINTT consortium.

Aging Clin Exp Res. 2017 Feb;29(1):3-10. doi: 10.1007/s40520-016-0712-5. Epub 2017 Feb 2.

PMID:
28155179
19.

The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods.

Landi F, Cesari M, Calvani R, Cherubini A, Di Bari M, Bejuit R, Mshid J, Andrieu S, Sinclair AJ, Sieber CC, Vellas B, Topinkova E, Strandberg T, Rodriguez-Manas L, Lattanzio F, Pahor M, Roubenoff R, Cruz-Jentoft AJ, Bernabei R, Marzetti E; SPRINTT Consortium.

Aging Clin Exp Res. 2017 Feb;29(1):89-100. doi: 10.1007/s40520-016-0715-2. Epub 2017 Jan 31.

PMID:
28144914
20.

The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people.

Bernabei R, Mariotti L, Bordes P, Roubenoff R.

Aging Clin Exp Res. 2017 Feb;29(1):1-2. doi: 10.1007/s40520-016-0707-2. Epub 2017 Jan 31. No abstract available.

PMID:
28144913
21.

Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

Vellas B, Fielding R, Bhasin S, Cerreta F, Goodpaster B, Guralnik JM, Kritchevsky S, Legrand V, Forkin C, Magaziner J, Morley JE, Rodriguez-Manas L, Roubenoff R, Studenski S, Villareal DT, Cesari M; International Conference on Frailtyand Sarcopenia Research Task Force.

J Frailty Aging. 2016;5(4):194-200.

PMID:
27883164
22.

Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly.

Brzeszczyńska J, Johns N, Schilb A, Degen S, Degen M, Langen R, Schols A, Glass DJ, Roubenoff R, Greig CA, Jacobi C, Fearon KCh, Ross JA.

Aging (Albany NY). 2016 Aug;8(8):1690-702. doi: 10.18632/aging.101006.

23.

PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.

Cesari M, Fielding R, Bénichou O, Bernabei R, Bhasin S, Guralnik JM, Jette A, Landi F, Pahor M, Rodriguez-Manas L, Rolland Y, Roubenoff R, Sinclair AJ, Studenski S, Travison T, Vellas B.

J Frailty Aging. 2015;4(3):114-120.

24.

Serum Leptin Levels and the Risk of Stroke: The Framingham Study.

Saber H, Himali JJ, Shoamanesh A, Beiser A, Pikula A, Harris TB, Roubenoff R, Romero JR, Kase CS, Vasan RS, Seshadri S.

Stroke. 2015 Oct;46(10):2881-5. doi: 10.1161/STROKEAHA.115.009463. Epub 2015 Sep 3.

25.

Treatment of sporadic inclusion body myositis with bimagrumab.

Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA.

Neurology. 2014 Dec 9;83(24):2239-46. doi: 10.1212/WNL.0000000000001070. Epub 2014 Nov 7.

26.

Prospect for pharmacological therapies to treat skeletal muscle dysfunction.

Meriggioli MN, Roubenoff R.

Calcif Tissue Int. 2015 Mar;96(3):234-42. doi: 10.1007/s00223-014-9926-8. Epub 2014 Nov 4. Review.

PMID:
25363509
27.

Influence of exercise on the metabolic profile caused by 28 days of bed rest with energy deficit and amino acid supplementation in healthy men.

Brooks NE, Cadena SM, Cloutier G, Vega-López S, Roubenoff R, Castaneda-Sceppa C.

Int J Med Sci. 2014 Sep 21;11(12):1248-57. doi: 10.7150/ijms.9694. eCollection 2014.

28.

Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy.

Westwood AJ, Beiser A, Decarli C, Harris TB, Chen TC, He XM, Roubenoff R, Pikula A, Au R, Braverman LE, Wolf PA, Vasan RS, Seshadri S.

Neurology. 2014 May 6;82(18):1613-9. doi: 10.1212/WNL.0000000000000382. Epub 2014 Apr 4.

29.

Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle.

Johns N, Hatakeyama S, Stephens NA, Degen M, Degen S, Frieauff W, Lambert C, Ross JA, Roubenoff R, Glass DJ, Jacobi C, Fearon KC.

PLoS One. 2014 Jan 3;9(1):e83618. doi: 10.1371/journal.pone.0083618. eCollection 2014.

30.

The "cytokine for gerontologists" has some company.

Roubenoff R.

J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):163-4. doi: 10.1093/gerona/glt184. Epub 2013 Dec 10. No abstract available.

PMID:
24325895
31.

Cardiometabolic risks during anabolic hormone supplementation in older men.

He J, Bhasin S, Binder EF, Yarasheski KE, Castaneda-Sceppa C, Schroeder ET, Roubenoff R, Chou CP, Azen SP, Sattler FR.

Obesity (Silver Spring). 2013 May;21(5):968-75. doi: 10.1002/oby.20081.

32.

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin-Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE, Vellas B; International Working Group on Sarcopenia.

J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):181-90. doi: 10.1007/s13539-012-0078-2. Epub 2012 Aug 3.

33.

Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of U.S. adults.

Sakakeeny L, Roubenoff R, Obin M, Fontes JD, Benjamin EJ, Bujanover Y, Jacques PF, Selhub J.

J Nutr. 2012 Jul;142(7):1280-5. doi: 10.3945/jn.111.153056. Epub 2012 May 23.

34.

Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review.

Steiner MC, Roubenoff R, Tal-Singer R, Polkey MI.

Thorax. 2012 Dec;67(12):1102-9. doi: 10.1136/thoraxjnl-2012-201765. Epub 2012 May 5. Review.

PMID:
22561528
35.
36.

Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).

Abellan van Kan G, Cderbaum JM, Cesari M, Dahinden P, Fariello RG, Fielding RA, Goodpaster BH, Hettwer S, Isaac M, Laurent D, Morley JE, Pahor M, Rooks D, Roubenoff R, Rutkove SB, Shaheen A, Vamvakas S, Vrijbloed JW, Vellas B.

J Nutr Health Aging. 2011 Dec;15(10):834-46. No abstract available.

PMID:
22159770
37.

Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation.

Schroeder ET, He J, Yarasheski KE, Binder EF, Castaneda-Sceppa C, Bhasin S, Dieli-Conwright CM, Kawakubo M, Roubenoff R, Azen SP, Sattler FR.

Eur J Appl Physiol. 2012 Mar;112(3):1123-31. doi: 10.1007/s00421-011-2077-y. Epub 2011 Jul 12.

38.

Sarcopenia with limited mobility: an international consensus.

Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan BA, Mantovani G, Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD; Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop.

J Am Med Dir Assoc. 2011 Jul;12(6):403-9. doi: 10.1016/j.jamda.2011.04.014.

39.

Whole-body and muscle protein metabolism are not affected by acute deviations from habitual protein intake in older men: the Hormonal Regulators of Muscle and Metabolism in Aging (HORMA) Study.

Yarasheski KE, Castaneda-Sceppa C, He J, Kawakubo M, Bhasin S, Binder EF, Schroeder ET, Roubenoff R, Azen SP, Sattler FR.

Am J Clin Nutr. 2011 Jul;94(1):172-81. doi: 10.3945/ajcn.110.010959. Epub 2011 May 4.

40.

Durability of the effects of testosterone and growth hormone supplementation in older community-dwelling men: the HORMA Trial.

Sattler FR, Bhasin S, He J, Yarasheski KE, Binder EF, Schroeder ET, Castaneda-Sceppa C, Kawakubo M, Roubenoff R, Dunn M, Hahn C, Stewart Y, Martinez C, Azen SP.

Clin Endocrinol (Oxf). 2011 Jul;75(1):103-11. doi: 10.1111/j.1365-2265.2011.04014.x.

41.

Dietary intakes of arachidonic acid and alpha-linolenic acid are associated with reduced risk of hip fracture in older adults.

Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL.

J Nutr. 2011 Jun;141(6):1146-53. doi: 10.3945/jn.110.133728. Epub 2011 Apr 20.

42.

Causal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis.

Xing H, McDonagh PD, Bienkowska J, Cashorali T, Runge K, Miller RE, Decaprio D, Church B, Roubenoff R, Khalil IG, Carulli J.

PLoS Comput Biol. 2011 Mar;7(3):e1001105. doi: 10.1371/journal.pcbi.1001105. Epub 2011 Mar 10.

43.

Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study.

Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL.

Am J Clin Nutr. 2011 May;93(5):1142-51. doi: 10.3945/ajcn.110.005926. Epub 2011 Mar 2.

44.

Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.

Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, Izmailova ES, Roubenoff R, Shadick NA, Weinblatt ME, Centola M, Lee DM.

Arthritis Rheum. 2011 Apr;63(4):894-903. doi: 10.1002/art.30213.

45.

Recent advances in the biology and therapy of muscle wasting.

Glass D, Roubenoff R.

Ann N Y Acad Sci. 2010 Nov;1211:25-36. doi: 10.1111/j.1749-6632.2010.05809.x. Review.

PMID:
21062293
46.

Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial.

Sattler F, Bhasin S, He J, Chou CP, Castaneda-Sceppa C, Yarasheski K, Binder E, Schroeder ET, Kawakubo M, Zhang A, Roubenoff R, Azen S.

J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):122-9. doi: 10.1093/gerona/glq183. Epub 2010 Nov 8.

47.

Effects of resistance exercise combined with essential amino acid supplementation and energy deficit on markers of skeletal muscle atrophy and regeneration during bed rest and active recovery.

Brooks NE, Cadena SM, Vannier E, Cloutier G, Carambula S, Myburgh KH, Roubenoff R, Castaneda-Sceppa C.

Muscle Nerve. 2010 Dec;42(6):927-35. doi: 10.1002/mus.21780. Epub 2010 Oct 6.

48.

Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.

Newman CB, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, Schwartzbard A, Kleinberg DL.

J Clin Endocrinol Metab. 2011 Jan;96(1):122-32. doi: 10.1210/jc.2010-1204. Epub 2010 Oct 6.

PMID:
20926529
49.

Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.

Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S.

JAMA. 2009 Dec 16;302(23):2565-72. doi: 10.1001/jama.2009.1836.

50.

Malnutrition syndromes: a conundrum vs continuum.

Jensen GL, Bistrian B, Roubenoff R, Heimburger DC.

JPEN J Parenter Enteral Nutr. 2009 Nov-Dec;33(6):710-6. doi: 10.1177/0148607109344724.

PMID:
19892905

Supplemental Content

Loading ...
Support Center